Tag Archive for: Dragonfly Therapeutics

Bristol Myers Squibb returned the rights for interleukin-12 (IL-12) immunotherapy program DF6002 to its original owner, Dragonfly Therapeutics, the companies announced Monday. 

It might seem like luck for a company to trip over a multi-billion dollar COVID treatment already lurking in its pipeline – but perhaps not so much when that company, Gilead, has been at the leading edge of antiviral R&D for decades.